The DOI matches its Crossref record; 302 of the 303 references it cites were found in a registry or an index.
Fluid Biomarkers for Synaptic Dysfunction and Loss
Open accessAbstract
Synapses are the site for brain communication where information is transmitted between neurons and stored for memory formation. Synaptic degeneration is a global and early pathogenic event in neurodegenerative disorders with reduced levels of pre- and postsynaptic proteins being recognized as a core feature of Alzheimer's disease (AD) pathophysiology. Together with AD, other neurodegenerative and neurodevelopmental disorders show altered synaptic homeostasis as an important pathogenic event, and due to that, they are commonly referred to as synaptopathies. The exact mechanisms of synapse dysfunction in the different diseases are not well understood and their study would help understanding the pathogenic role of synaptic degeneration, as well as differences and commonalities among them and highlight candidate synaptic biomarkers for specific disorders. The assessment of synaptic proteins in cerebrospinal fluid (CSF), which can reflect synaptic dysfunction in patients with cognitive disorders, is a keen area of interest. Substantial research efforts are now directed toward the investigation of CSF synaptic pathology to improve the diagnosis of neurodegenerative disorders at an early stage as well as to monitor clinical progression. In this review, we will first summarize the pathological events that lead to synapse loss and then discuss the available data on established (eg, neurogranin, SNAP-25, synaptotagmin-1, GAP-43, and α-syn) and emerging (eg, synaptic vesicle glycoprotein 2A and neuronal pentraxins) CSF biomarkers for synapse dysfunction, while highlighting possible utilities, disease specificity, and technical challenges for their detection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, synapses may promote the spread of aberrant proteins via prion-like mechanisms, thus enhancing neurodegeneration (Camporesi et al. 2020; Gong and Lippa 2010; Swanson et al. 2018).”
From Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration (2022) · cites this paper as Camporesi et al. 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–302 of 302
Manek, R., Moghieb, A. M., Yang, Z., Kumar, D., Kobeissy, F. H., Sarkis, G. A., Raghavan, V., & Wang, K. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0909-z · Cited by 109
Synaptotagmin 1 clamps synaptic vesicle fusion in mammalian neurons independent of complexin
Courtney, N. A., Bao, H., Briguglio, J. S., & Chapman, E. R. (2019) · Nature Communications · doi:10.1038/s41467-019-12015-w · Cited by 108
Puzzling Out Synaptic Vesicle 2 Family Members Functions
Bartholome, O., Van den Ackerveken, P., Sánchez Gil, J., de la Brassinne Bonardeaux, O., Leprince, P., Franzen, R., & Rogister, B. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00148 · Cited by 107
Synucleinopathies: Where we are and where we need to go
Brás, I. C., Dominguez‐Meijide, A., Gerhardt, E., Koss, D. J., Lázaro, D. F., Santos, P. I., Vasili, E., Xylaki, M., & Outeiro, T. F. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.14965 · Cited by 106
Potent prion-like behaviors of pathogenic α-synuclein and evaluation of inactivation methods
Tarutani, A., Arai, T., Murayama, S., Hisanaga, S., & Hasegawa, M. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0532-2 · Cited by 105
Younan, N. D., Sarell, C. J., Davies, P., Brown, D. R., & Viles, J. H. (2013) · The FASEB Journal · doi:10.1096/fj.12-222588 · Cited by 104
Clinical Use and Utility of Amyloid Imaging
Barthel, H., & Sabri, O. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.185017 · Cited by 102
Validation of 14-3-3 Protein as a Marker in Sporadic Creutzfeldt-Jakob Disease Diagnostic
Schmitz, M., Ebert, E., Stoeck, K., Karch, A., Collins, S. J., Calero, M., Sklaviadis, T., Laplanche, J., Golańska, E., Baldeiras, I., et al. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9167-5 · Cited by 102
Interactions between Neurogranin and Calmodulin in Vivo
Prichard, L. B., Deloulme, J., & Storm, D. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.7689 · Cited by 101
CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders
Mondello, S., Constantinescu, R., Zetterberg, H., Andréasson, U., Holmberg, B., & Jeromin, A. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.01.011 · Cited by 100
Self-citationRemnestål, J., Just, D., Mitsios, N., Fredolini, C., Mulder, J., Schwenk, J. M., Uhlén, M., Kultima, K., Ingelsson, M., Kilander, L., et al. (2016) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201500150 · Cited by 98
Self-citationTau-mediated synaptic damage in Alzheimer’s disease
Jadhav, S., Cubinkova, V., Zimova, I., Brezováková, V., Maďari, A., Cigánková, V., & Žilka, N. (2015) · Translational Neuroscience · doi:10.1515/tnsci-2015-0023 · Cited by 97
Savica, R., Grossardt, B. R., Bower, J. H., Ahlskog, J. E., Boeve, B. F., Graff‐Radford, J., Rocca, W. A., & Mielke, M. M. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.0603 · Cited by 97
Initiative, T. A. D. N., Zhang, H., Therriault, J., Kang, M. S., Ng, K. P., Pascoal, T. A., Rosa‐Neto, P., & Gauthier, S. G. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0407-6 · Cited by 97
Dementia in Parkinson's disease
Aarsland, D., Beyer, M. K., & Kurz, M. W. (2008) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283168df0 · Cited by 95
Abnormal synaptic pruning in schizophrenia: Urban myth or reality?
Boksa, P. (2012) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.120007 · Cited by 94
Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimer’s Disease
Oeckl, P., Halbgebauer, S., Anderl‐Straub, S., Arnim, C. A. F. V., Diehl‐Schmid, J., Froelich, L., Grimmer, T., Hausner, L., Denk, J., Jahn, H., et al. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00824 · Cited by 93
Synaptotagmin, a synaptic vesicle protein, is present in human cerebrospinal fluid
Davidsson, P., Jahn, R., Bergquist, J., Ekman, R., & Blennow, K. (1996) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815094 · Cited by 89
Self-citationSekiya, H., Kowa, H., Koga, H., Takata, M., Satake, W., Futamura, N., Funakawa, I., Jinnai, K., Takahashi, M., Kondo, T., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01961-w · Cited by 89
Bougea, A. M., Stefanis, L., Paraskevas, G. P., Emmanouilidou, E., Vekrelis, K., & Kapaki, E. N. (2019) · Neurological Sciences · doi:10.1007/s10072-019-03738-1 · Cited by 88
Salivary alpha-synuclein in the diagnosis of Parkinson's disease and Progressive Supranuclear Palsy
Vivacqua, G., Suppa, A., Mancinelli, R., Belvisi, D., Fabbrini, A., Costanzo, M., Formica, A., Onori, P., Fabbrini, G., & Berardelli, A. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.02.014 · Cited by 88
Canas, P. M., Simões, A. P., Rodrigues, R. J., & Cunha, R. A. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.026 · Cited by 86
A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease
Ashton, N. J., Nevado‐Holgado, A. J., Barber, I., Lynham, S., Gupta, V. B., Chatterjee, P., Goozee, K. G., Hone, E., Pedrini, S., Blennow, K., et al. (2019) · Science Advances · doi:10.1126/sciadv.aau7220 · Cited by 86
Self-citationBrito-Moreira, J., Lourenco, M. V., Oliveira, M. M., Ribeiro, F. C., Ledo, J. H., Diniz, L. P., Vital, J. F. S., Magdesian, M. H., Melo, H. M., Barros-Aragão, F., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.761189 · Cited by 84
Fluorodeoxyglucose PET in Neurology and Psychiatry
Schöll, M., Damián, A., & Engler, H. (2014) · PET Clinics · doi:10.1016/j.cpet.2014.07.005 · Cited by 83
Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease
Tible, M., Sandelius, Å., Höglund, K., Brinkmalm, A., Cognat, E., Dumurgier, J., Zetterberg, H., Hugon, J., Paquet, C., & Blennow, K. (2020) · Neurology · doi:10.1212/wnl.0000000000010131 · Cited by 83
Self-citationOligomeric α-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson’s disease
Пчелина, С. Н., Emelyanov, A., Baydakova, G., Andoskin, P. A., Senkevich, K. A., Nikolaev, M. A., Miliukhina, I. V., Yakimovskii, А. F., Timofeeva, A., Fedotova, E. Y., et al. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.10.039 · Cited by 82
Kapaki, E. N., Paraskevas, G. P., Emmanouilidou, E., & Vekrellis, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081654 · Cited by 81
Tanner, V., Ploug, T., & Tao-Cheng, J.-H. (1996) · Journal of Histochemistry & Cytochemistry · doi:10.1177/44.12.8985140 · Cited by 80
Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls
Kroksveen, A. C., Guldbrandsen, A., Vedeler, C., Myhr, K. M., Opsahl, J. A., & Berven, F. S. (2012) · Acta Neurologica Scandinavica · doi:10.1111/ane.12029 · Cited by 80
Swanson, A., & Willette, A. A. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.07.148 · Cited by 79
The A/T/N biomarker scheme and patterns of brain atrophy assessed in mild cognitive impairment
Ekman, U., Ferreira, D., & Westman, E. (2018) · Scientific Reports · doi:10.1038/s41598-018-26151-8 · Cited by 79
Altered Synapse Stability in the Early Stages of Tauopathy
Jackson, J., Witton, J., Johnson, J. D., Ahmed, Z., Ward, M., Randall, A. D., Hutton, M. L., Isaac, J. T. R., O’Neill, M. J., & Ashby, M. C. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.013 · Cited by 78
CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD
Blennow, K., Lucena, D. D., Zetterberg, H., Villar‐Piqué, A., Karch, A., Vidal, E., Hermann, P., Schmitz, M., Ferrer, I., Zerr, I., et al. (2019) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-320155 · Cited by 78
Self-citationSynaptic vesicle protein 2A as a potential biomarker in synaptopathies
Heurling, K., Ashton, N. J., Leuzy, A., Zimmer, E. R., Blennow, K., Zetterberg, H., Eriksson, J., Lubberink, M., & Schöll, M. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.02.001 · Cited by 77
Self-citationSalivary total α-synuclein, oligomeric α-synuclein and SNCA variants in Parkinson’s disease patients
Kang, W., Chen, W., Yang, Q., Zhang, L., Zhang, L., Wang, X., Dong, F., Zhao, Y., Chen, D., Quinn, T. J., et al. (2016) · Scientific Reports · doi:10.1038/srep28143 · Cited by 76
Antonell, A., Tort‐Merino, A., Ríos, J., Balasa, M., Borrego‐Écija, S., Auge, J. M., Muñoz‐García, C., Bosch, B., Falgàs, N., Rami, L., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.09.001 · Cited by 76
Self-citationBenedet, A. L., Ashton, N. J., Pascoal, T. A., Leuzy, A., Mathotaarachchi, S. S., Kang, M. S., Therriault, J., Savard, M., Chamoun, M., Schöll, M., et al. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.08.002 · Cited by 75
Self-citationSynaptic proteins in CSF relate to Parkinson’s disease stage markers
Bereczki, E., Bogstedt, A., Höglund, K., Tsitsi, P., Brodin, L., Ballard, C., Svenningsson, P., & Aarsland, D. (2017) · npj Parkinson's Disease · doi:10.1038/s41531-017-0008-2 · Cited by 72
Williams, S. M., Schulz, P., & Sierks, M. R. (2015) · European Journal of Neuroscience · doi:10.1111/ejn.13056 · Cited by 71
α-Synuclein in Extracellular Vesicles: Functional Implications and Diagnostic Opportunities
Lööv, C., Scherzer, C. R., Hyman, B. T., Breakefield, X. O., & Ingelsson, M. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0317-0 · Cited by 68
Ding, Y. J., Zhao, J., Zhang, X., Wang, S., Viola, K. L., Chow, F. E., Zhang, Y., Lippa, C. F., Klein, W. L., & Gong, Y. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01140 · Cited by 68
Zhou, B., Wen, M., Yu, W., Zhang, C., & Jiao, L. (2015) · Parkinson s Disease · doi:10.1155/2015/567386 · Cited by 65
Models of synaptotagmin‐1 to trigger Ca 2+ ‐dependent vesicle fusion
Park, Y., & Ryu, J. (2018) · FEBS Letters · doi:10.1002/1873-3468.13193 · Cited by 65
Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics
van der Ende, E. L., Meeter, L. H., Stingl, C., van Rooij, J. G. J., Stoop, M. P., Nijholt, D. A. T., Sanchez‐Valle, R., Graff, C., Öijerstedt, L., Grossman, M., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.745 · Cited by 65
Daniele, S., Frosini, D., Pietrobono, D., Petrozzi, L., Gerfo, A. L., Baldacci, F., Fusi, J., Giacomelli, C., Siciliano, G., Trincavelli, M. L., et al. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00053 · Cited by 63
Ishii, R., Tokuda, T., Tatebe, H., Ohmichi, T., Kasai, T., Nakagawa, M., Mizuno, T., & El‐Agnaf, O. M. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123162 · Cited by 60
Choo, I. H., Ni, R., Schöll, M., Wall, A. E., Almkvist, O., & Nordberg, A. K. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121489 · Cited by 59
Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study
Willemse, E. A. J., Vos, A. D., Herries, E. M., Andréasson, U., Engelborghs, S., van der Flier, W. M., Scheltens, P., Crimmins, D. L., Ladenson, J. H., Vanmechelen, E., et al. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2017.283028 · Cited by 58
Self-citationClarke, M. T. M., Brinkmalm, A., Foiani, M. S., Woollacott, I. O. C., Heller, C., Heslegrave, A., Keshavan, A., Fox, N. C., Schott, J. M., Warren, J. D., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0564-2 · Cited by 58
Self-citationLlorens, F., Kruse, N., Schmitz, M., Gotzmann, N., Golańska, E., Thüne, K., Zejneli, O., Kanata, Ε., Knipper, T., Cramm, M., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.09.013 · Cited by 57
Wesenhagen, K. E. J., Teunissen, C. E., Visser, P. J., & Tijms, B. M. (2019) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1670613 · Cited by 57
Mollenhauer, B., Bowman, F. D., Drake, D. F., Duong, J., Blennow, K., El‐Agnaf, O. M. A., Shaw, L. M. J., Masucci, J., Taylor, P., Umek, R. M., et al. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14569 · Cited by 55
Self-citationBlood Contamination in CSF and Its Impact on Quantitative Analysis of Alpha-Synuclein
Barkovits, K., Kruse, N., Linden, A., Tönges, L., Pfeiffer, K., Mollenhauer, B., & Marcus, K. (2020) · Cells · doi:10.3390/cells9020370 · Cited by 55
Majbour, N. K., Chiasserini, D., Vaikath, N. N., Eusebi, P., Tokuda, T., van de Berg, W., Parnetti, L., Calabresi, P., & El-Agnaf, O. M. A. (2017) · Scientific Reports · doi:10.1038/srep40263 · Cited by 55
Cerebrospinal Fluid Biomarkers in Idiopathic Normal Pressure Hydrocephalus
Leinonen, V., Menon, L. G., Carroll, R. S., DelloIacono, D. M., Grevet, J. D., Jääskeläinen, J. E., & Black, P. M. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/312526 · Cited by 51
Elhadi, S. A., Honig, A., Simhi-Haham, D., Schechter, M., Linetsky, E., Ben‐Hur, T., & Sharon, R. (2015) · Scientific Reports · doi:10.1038/srep11120 · Cited by 51
Begcevic, I., Tsolaki, M., Brinc, D., Brown, M., Martinez-Morillo, E., Lazarou, I., Kozori, M., Tagaraki, F., Nenopoulou, S., Gkioka, M., et al. (2018) · F1000Research · doi:10.12688/f1000research.15095.1 · Cited by 51
Antibody‐based profiling of cerebrospinal fluid within multiple sclerosis
Månberg, A., Byström, S., Ayoglu, B., Qundos, U., Uhlén, M., Khademi, M., Olsson, T. P., Schwenk, J. M., & Nilsson, P. (2013) · PROTEOMICS · doi:10.1002/pmic.201200580 · Cited by 50
Lista, S., (APMI), F. T. A. P. M. I., Toschi, N., Baldacci, F., Zetterberg, H., Blennow, K., Kilimann, I., Teipel, S. J., Cavedo, E., dos Santos, A. M., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170368 · Cited by 50
Self-citationLlano, D. A., Bundela, S., Mudar, R. A., Devanarayan, V., & Initiative, A. D. N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182098 · Cited by 49
Veleri, S., Punnakkal, P., Dunbar, G. L., & Maiti, P. (2018) · NeuroMolecular Medicine · doi:10.1007/s12017-018-8479-9 · Cited by 49
Sanfilippo, C., Forlenza, O. V., Zetterberg, H., & Blennow, K. (2016) · Journal of Neural Transmission · doi:10.1007/s00702-016-1597-3 · Cited by 49
Self-citationMagdalinou, N. K., Noyce, A. J., Pinto, R., Lindstrom, E., Holmén-Larsson, J., Holtta, M., Blennow, K., Morris, H. R., Skillbäck, T., Warner, T. T., et al. (2017) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.01.016 · Cited by 49
Self-citation14-3-3 Proteins in Glutamatergic Synapses
Zhang, J., & Zhou, Y. (2018) · Neural Plasticity · doi:10.1155/2018/8407609 · Cited by 48
The vascular side of Alzheimer's disease
Liesz, A. (2019) · Science · doi:10.1126/science.aay2720 · Cited by 48
Validation of α-Synuclein as a CSF Biomarker for Sporadic Creutzfeldt-Jakob Disease
Llorens, F., Kruse, N., Karch, A., Schmitz, M., Zafar, S., Gotzmann, N., Sun, T., Köchy, S., Knipper, T., Cramm, M., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0479-5 · Cited by 48
Blennow, K., Davidsson, P., Wallin, A., & Ekman, R. (1995) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000106963 · Cited by 47
Self-citationSoldan, A., Moghekar, A., Walker, K. A., Pettigrew, C. A., Hou, X., Lu, H., Miller, M. I., Alfini, A. J., Albert, M., Xu, D., et al. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00132 · Cited by 45
Synaptic actin stabilization protein loss in Down syndrome and Alzheimer disease
Lauterborn, J. C., Cox, C. D., Chan, S. W., Vanderklish, P. W., Lynch, G., & Gall, C. M. (2020) · Brain Pathology · doi:10.1111/bpa.12779 · Cited by 43
Alpha-Synuclein Continues to Enhance SNARE-Dependent Vesicle Docking at Exorbitant Concentrations
Hawk, B. J. D., Khounlo, R., & Shin, Y. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00216 · Cited by 42
Sanderson, J. B., De, S., Jiang, H., Rovere, M., Jin, M., Zaccagnini, L., Watson, A. H., de Boni, L., Lagomarsino, V. N., Young‐Pearse, T. L., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa010 · Cited by 41
The relation between plasma α-synuclein level and clinical symptoms or signs of Parkinson's disease
Malec‐Litwinowicz, M., Plewka, A., Plewka, D., Bogunia, E., Morek, M., Szczudlik, A., Szubiga, M., & Rudzińska, M. (2017) · Neurologia i Neurochirurgia Polska · doi:10.1016/j.pjnns.2017.11.009 · Cited by 40
Filippi, L., Chiaravalloti, A., Bagni, O., & Schillaci, O. (2018) · Europe PMC (PubMed Central) · Cited by 40
Kušnierová, P., Zeman, D., Hradílek, P., Čábal, M., & Zapletalová, O. (2019) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.22948 · Cited by 39
Wang, Z.-Y., Han, Z.-M., Liu, Q.-F., Tang, W., Ye, K., & Yao, Y.-Y. (2015) · International Psychogeriatrics · doi:10.1017/s1041610215000447 · Cited by 39
Lim, B., Sando, S. B., Grøntvedt, G. R., Bråthen, G., & Diamandis, E. P. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.03.013 · Cited by 39
Laske, C., Fallgatter, A. J., Stransky, E., Hagen, K., Berg, D., & Maetzler, W. (2011) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000329763 · Cited by 38
Jurcău, A., & Simion, A. (2020) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319666200303121016 · Cited by 38
Neurogranin binds to phosphatidic acid and associates to cellular membranes
Domínguez-González, I., Vázquez‐Cuesta, S., Algaba, A., & Díez-Guerra, F. J. (2007) · Biochemical Journal · doi:10.1042/bj20061483 · Cited by 36
Potential Diagnostic Value of Red Blood Cells α-Synuclein Heteroaggregates in Alzheimer’s Disease
Baldacci, F., Daniele, S., Piccarducci, R., Giampietri, L., Pietrobono, D., Giorgi, F. S., Nicoletti, V., Frosini, D., Libertini, P., Gerfo, A. L., et al. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1531-4 · Cited by 36
Öhrfelt, A., Brinkmalm, A., Dumurgier, J., Zetterberg, H., Bouaziz-Amar, É., Hugon, J., Paquet, C., & Blennow, K. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.11.038 · Cited by 35
Self-citationBecker, B., Nazir, F. H., Brinkmalm, G., Camporesi, E., Kvartsberg, H., Portelius, E., Boström, M., Kalm, M., Höglund, K., Olsson, M., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0279-z · Cited by 34
Self-citationChatterjee, M., del Campo, M., Morrema, T. H. J., de Waal, M. W. J., van der Flier, W. M., Hoozemans, J. J. M., & Teunissen, C. E. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0383-x · Cited by 33
Transient increase in CSF GAP-43 concentration after ischemic stroke
Sandelius, Å., Cullen, N. C., Källén, Å., Rosengren, L., Jensen, C., Kostanjevečki, V., Vandijck, M. L. J., Zetterberg, H., & Blennow, K. (2018) · BMC Neurology · doi:10.1186/s12883-018-1210-5 · Cited by 33
Self-citationWang, H., Stewart, T., Toledo, J. B., Ginghina, C., Tang, L., Atik, A., Aro, P., Shaw, L. M., Trojanowski, J. Q., Galasko, D. R., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171013 · Cited by 33
New insights into atypical parkinsonism
Wenning, G. K., Krismer, F., & Poewe, W. H. (2011) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283480569 · Cited by 32
Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update
Oeckl, P., Steinacker, P., Feneberg, E., & Otto, M. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13669 · Cited by 30
Chromogranin A in the early steps of the neurosecretory pathway
Laguerre, F., Anouar, Y., & Montero‐Hadjadje, M. (2019) · IUBMB Life · doi:10.1002/iub.2218 · Cited by 30
Berge, G., Sando, S. B., Albrektsen, G., Lauridsen, C., Møller, I., Grøntvedt, G. R., Bråthen, G., & White, L. R. (2016) · BMC Neurology · doi:10.1186/s12883-016-0706-0 · Cited by 29
Wang, C., Zhao, D., Shah, S. Z. A., Yang, W., Li, C., & Yang, L. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0029-6 · Cited by 27
APOE ε4 is associated with higher levels of CSF SNAP-25 in prodromal Alzheimer’s disease
Wang, S., Zhang, J., & Pan, T. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.08.029 · Cited by 27
Schmitz, M., Villar‐Piqué, A., Llorens, F., Gmitterová, K., Hermann, P., Varges, D., Zafar, S., Lingor, P., Vanderstichele, H., Demeyer, L., et al. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1313-4 · Cited by 26
Lim, B., Tsolaki, M., Soosaipillai, A., Brown, M., Zilakaki, M., Tagaraki, F., Fotiou, D., Koutsouraki, E., Grosi, E., Prassas, I., et al. (2019) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-0428 · Cited by 25
Cortical gray matter loss in schizophrenia: Could microglia be the culprit?
Rački, V., Petrić, D., Kučić, N., Gržeta, N., Jurdana, K., & Rončević-Gržeta, I. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2015.12.021 · Cited by 22
Quantitative mass spectrometry reveals changes in SNAP-25 isoforms in schizophrenia
Barakauskas, V., Moradian, A., Barr, A. M., Beasley, C. L., Rosoklija, G. B., Mann, J. J., Ilievski, B., Stankov, A., Dwork, A. J., Falkai, P., et al. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.03.002 · Cited by 20
Schlaf, G., Salje, C., Wetter, A., Stuertz, K., Felgenhauer, K., & Mäder, M. (1998) · Journal of Immunological Methods · doi:10.1016/s0022-1759(98)00027-1 · Cited by 20
Multiple Origins of Sex Differences in Brain
Pfaff, D. W., & Christen, Y. (2013) · Research and perspectives in endocrine interactions · doi:10.1007/978-3-642-33721-5 · Cited by 13
Cerebrospinal fluid GAP-43 in early multiple sclerosis
Rot, U., Sandelius, Å., Emeršič, A., Zetterberg, H., & Blennow, K. (2018) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/2055217318792931 · Cited by 11
Self-citationKorade, Ž., & Mirnics, K. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.006 · Cited by 9
D’Alessandro, R., & Meldolesi, J. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.04.024 · Cited by 6
O2‐05‐01: CEREBROSPINAL FLUID SYNAPTIC VESICLE GLYCOPROTEIN 2A IN ALZHEIMER'S DISEASE
Ashton, N. J., Höglund, K., Leuzy, A., Heurling, K., Hugon, J., Dumurgier, J., Cognat, E., Paquet, C., Hansson, O., Schöll, M., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.06.4475 · Cited by 2
Self-citation
Flagged first, then by citations
1 of the 303 references couldn’t be matched to a known paper.
Research works printed but not linked: 7
- Dani M, 2018, Brain, 141, 2740
- 10.1212/WNL.56.1.127 · DOI · Paper page
- Baba M, 1998, Am J Pathol, 152, 879
- Filippi L, 2018, Am J Nucl Med Mol Imaging, 8, 268
- Zhou B, 2015, Parkinsons Dis, 2015, 567386
- Blennow K, 1995, Dementia, 6, 306
- Foote M, 2012, Int J Biochem Mol Biol, 3, 152
Cited by
Sorted by citations
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation
Teunissen, C. E., Verberk, I. M. W., Thijssen, E. H., Vermunt, L., Hansson, O., Zetterberg, H., van der Flier, W. M., Mielke, M. M., & del Campo, M. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00361-6 · Cited by 1,045
Self-citationPhosphorylated Tau in Alzheimer’s Disease and Other Tauopathies
Rawat, P., Sehar, U., Bisht, J., Selman, A., Culberson, J., & Reddy, P. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112841 · Cited by 509
Omics sciences for systems biology in Alzheimer’s disease: State-of-the-art of the evidence
Hampel, H. J., Nisticò, R., Seyfried, N. T., Levey, A. I., Modeste, E. S., Lemercier, P., Baldacci, F., Toschi, N., Garaci, F., Perry, G. L., et al. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101346 · Cited by 147
Milà‐Alomà, M., Brinkmalm, A., Ashton, N. J., Kvartsberg, H., Shekari, M., Operto, G., Salvadó, G., Falcón, C., Gispert, J. D., Vilor‐Tejedor, N., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012853 · Cited by 118
Self-citationGómez de San José, N., Massa, F., Halbgebauer, S., Oeckl, P., Steinacker, P., & Otto, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02411-2 · Cited by 112
Metadata
- Authors
- Camporesi, E., Nilsson, J., Brinkmalm, A., Becker, B., Ashton, N. J., Blennow, K., & Zetterberg, H.
- Affiliations
- University of Gothenburg (SE)
- Sahlgrenska University Hospital (SE)
- King's College London (GB)
- Corresponding author
- Camporesi, Elena
- ORCID
- Venue
- Biomarker Insights
- Publisher
- SAGE Publications
- Published
- 2020-01
- Volume
- 15
- Pages
- 117727192095031
- ISSN
- 1177-2719 (ISSN-L)
- PMC
- PMC7444114
- OpenAlex
- W3080191672
- Cited by
- 165
- References
- 303
- Citations by year
- 2026: 19 · 2025: 30 · 2024: 33 · 2023: 23 · 2022: 35 · 2021: 23 · 2020: 2
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomarker Insights (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- synaptic dysfunction, synaptic loss, cerebrospinal fluid biomarkers, synaptopathy, neurodegenerative diseases, Alzheimer's disease, neurogranin, SNAP-25, synaptotagmin-1, GAP-43, alpha-synuclein, SV2A, synaptic proteins, early diagnosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
